This article was originally published in The Gray Sheet
Former parent firm Sulzer Ltd. initiates arbitration proceedings against the orthopedics firm seeking to "confirm legal validity and executability of Sulzer Medica's obligation to indemnify Sulzer Ltd." against device-related expenses and damage claims, Sulzer Ltd. says Dec. 20. "Over the past few weeks Sulzer Medica has...repeatedly denied any obligation to indemnify," Sulzer Ltd. claims. Sulzer Medica is seeking to settle claims related to its Inter-Op hip recall and Natural Knee II implant withdrawals via a proposed $783 mil. settlement (1"The Gray Sheet" Dec. 3, 2001, p. 20)...
You may also be interested in...
An agreement attempting to resolve the suit between Sulzer Orthopedics and injured parties through a third party signals a recognition by plaintiffs that the litigation could bankrupt parent Sulzer Medica, according to the Winterhur, Switzerland company
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.